Organisation paid for research Program year 2024 Source: CMS Open Payments

Best Quality Research Inc.

Neither a doctor nor a teaching hospital

Research payments

$60,913

80 payments

Through program year 2024, Best Quality Research Inc. is reported as receiving $60,913 in research payments, across 80 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$1,656	4
2021	Research	$12,096	1
2020	Research	$7,918	32
2019	Research	$39,243	43

Breakdown

Who paid Research payments · program years 2019–2024

Merck Sharp & Dohme Corporation $59,257 76 payments
Moderna TX, Inc. $1,656 4 payments

Studies the money was for Research payments · program years 2019–2024

Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age $54,949 17 payments
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age $3,808 58 payments
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Mrna-1403, A Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults 18 Years of Age $1,656 4 payments
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V591 MV SARS-CoV-2, Live, Recombinant in Healthy Individuals 16 Years of Age or Older $500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.